Anadys
San Diego
About Anadys
Anadys Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines for the treatment of hepatitis C. The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $17.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2009)
- Ticker: nasdaq:ANDS
- Website: anadyspharma.com
Industries & Categories
Biopharma, Biotechnology, Clinical Trials
Social Profiles
Canonical: https://fsome.com/organization/anadys-2011923 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.